Lorus is a clinical stage cancer drug development company with a strong commitment to discovering and developing innovative molecular targeted therapies addressing major unmet medical needs.
Quote | Aptose Biosciences Inc. (NASDAQ:APTO)
Last: | $1.16 |
---|---|
Change Percent: | 2.46% |
Open: | $1.19 |
Close: | $1.16 |
High: | $1.235 |
Low: | $1.15 |
Volume: | 47,081 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | Aptose Biosciences Inc. (NASDAQ:APTO)
2024-03-26 20:38:02 ET Aptose Biosciences Inc. (APTO) Q4 2023 Earnings Conference Call March 26, 2024 05:00 PM ET Company Participants Susan Pietropaolo - Managing Director-Corporate Communications & Investor Relations William Rice - Chairman, President & Chi...
2024-03-26 16:50:27 ET More on Aptose Biosciences Aptose Biosciences prices 4.9M shares at $1.71 in underwritten public offering Seeking Alpha’s Quant Rating on Aptose Biosciences Historical earnings data for Aptose Biosciences Financial information fo...
Message Board Posts | Aptose Biosciences Inc. (NASDAQ:APTO)
Subject | By | Source | When |
---|---|---|---|
A nice short read on a PROTAC approach | dcaf7 | investorshub | 05/01/2023 12:22:38 AM |
Its not about revenue. | Tartiaboy | investorshub | 04/27/2023 7:20:11 PM |
The stock has dropped from the .60 area | Zeppo | investorshub | 04/25/2023 2:14:15 PM |
AML news. | dcaf7 | investorshub | 04/21/2023 5:09:01 PM |
TP53 rules. | Tartiaboy | investorshub | 04/20/2023 12:34:17 PM |
News, Short Squeeze, Breakout and More Instantly...
Aptose Biosciences Inc. Company Name:
APTO Stock Symbol:
NASDAQ Market:
Aptose Biosciences Inc. Website:
Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AML Tuspetinib Continues Broad Activity Across Mutations with Excellent Safety Profile Luxeptinib G3 Formulation Achieves Desired Levels and Positions for Future Trials Conference Call ...
Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...
SAN DIEGO and TORONTO, March 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical- stage precision oncology c...